Latest news

View all

Sweden – September 14, 2026

Sweden’s general election too close to call, final result due this weekend

Sweden’s general election on 13 September delivered a razor-thin result, with the Social Democrat-led opposition holding an apparent one-seat edge over PM Ulf Kristersson’s right-wing coalition as counting continues — leaving open the fate of an unusually broad cross-party consensus on pharmaceutical policy reform that emerged during the campaign.

Funding – September 14, 2026

Wallenberg Foundations grant AI support to 11 research groups

Eleven Swedish research groups, six of them in life science, have been awarded the new Knut and Alice Wallenberg AI Consultancy Grant, giving them access to dedicated AI expertise to accelerate their projects.

Science News – September 14, 2026

NADMED platform sets reference ranges for blood NAD and glutathione

A large population study using NADMED’s redox metabolite testing platform has established healthy reference ranges for NAD and glutathione, two key drivers of cellular energy metabolism, and identified distinct disease-related alterations in both from a single blood sample.

Denmark – September 10, 2026

Copenhagen to get new quantum chip facility

Quantum Foundry Copenhagen and the Novo Nordisk Foundation are building a 5,300m² quantum chip fabrication facility in Copenhagen, aiming to strengthen Europe’s position in the global quantum race.

Business Award – September 10, 2026

They won the Nordic Star 2026 Pitch Competition

AAX Biotech AB won the prestigious Nordic Star Pitch Competition at the Nordic Life Science Days (NLSDays) 2026.

Profiles in Business – September 9, 2026

Olivier Duchamp-Giudicelli: NLSDays’ accidental founder looks back

After a full career building life science communities and now approaching something akin to retirement – meaning only cherry-picking the projects that appeal to him – French-born Olivier Duchamp-Giudicelli reflects on the accidental advent of NLSDays in 2014, and how partnering and dealmaking have changed over the years.

14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • Closer to patients: We follow how putting patients at the center is reshaping life science across the Nordics – from a windswept bike ride across Iceland to negotiating tables where who ultimately gets access to new treatments is decided.
  • Women shaping life science: Exclusive interviews with five women shaping the industry, from executive leaders to scientists. Each shares her personal story, from the events and passions that shaped her career to concrete tips and advice for other women.
  • Business: We have spoken to Björn Odlander, co-founder of HealthCap, about the VC firm’s long-term approach and Europe’s widening capital gap. We have also taken a closer look at Stockholm’s journey to becoming a complete and globally competitive life science ecosystem.
  • In addition: Emma Lundberg shares her insights from conducting world-class cell-mapping science on two continents; we look back on 20 years of Finnish biotech; and we look ahead at our industry’s collective tasks for the next decade.
Subscribe now

Opinion & debate

Clinical Trials

Clinical Trials – September 9, 2026

Novo Nordisk’s semaglutide moves obesity below threshold in nearly half of children in phase 3 trial

In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.

Clinical Trials – September 8, 2026

SynAct’s new data analysis bolsters case for Phase 3 RA trial

A post-hoc analysis of SynAct Pharma’s Phase 2b ADVANCE study confirms earlier positive results for resomelagon in rheumatoid arthritis (RA), and the company now plans to discuss Phase 3 trial design with the FDA in Q4 2026.

Clinical Trials – September 2, 2026

Cinclus Pharma completes treatment phase in Phase III trial

The company has completed the eight-week treatment period for all patients in its pivotal Phase III HEEALING1 study of linaprazan glurate in erosive gastroesophageal reflux disease (GERD), with topline results now expected in the fourth quarter of 2026.

Clinical Trials – August 31, 2026

AstraZeneca’s Tezspire hits primary endpoints in Phase III trial

AstraZeneca and partner Amgen have reported that Tezspire (tezepelumab) met both co-primary and all key secondary endpoints in the Phase III CROSSING trial in eosinophilic esophagitis (EoE), positioning the anti-TSLP antibody for a potential new indication beyond its existing approvals in severe asthma and chronic rhinosinusitis with nasal polyps.

Clinical Trials – August 31, 2026

Faron enrolls first patient in investigator-initiated Phase 1b/2 trial

Faron Pharmaceuticals has announced that the first patient has been enrolled in the BEXAR trial, testing its lead candidate bexmarilimab in combination with chemotherapy as a first-line treatment for metastatic soft-tissue sarcoma.

Biotech Business – August 26, 2026

Lytix Biopharma enters major clinical collaboration in Europe

Lytix Biopharma is joining a new investigator-initiated Phase II study, ALETTA, that will test its lead candidate ruxotemitide in combination with ipilimumab and nivolumab in patients with early-stage, resectable melanoma – a second major checkpoint-inhibitor combination alongside the company’s existing pembrolizumab work.

Follow Nordic Life Science news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Science article – June 4, 2025

The science of aging better

All over the world, countries are experiencing a demographic shift towards aging populations. The field of aging research seeks to answer the question of how we can age healthier, and not just live longer.

Nobel Prize Laureate – December 20, 2014

Edvard & May-Britt Moser: Nobel Laureates in Medicine 2014

Chris Tachibana interviewed May-Britt and Edvard Moser about their discovery, science and sharing a passion in 2014.

Sponsored content

Evotec: Where human insight meets artificial intelligence

Artificial intelligence is rapidly reshaping drug discovery and development, and the companies making real progress are those that treat AI as an accelerator, not a replacement, for scientific judgement.

Follow Nordic Life Science news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Explore topics

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.